Genetic testing by cancer site: stomach
- PMID: 22846738
- DOI: 10.1097/PPO.0b013e31826246dc
Genetic testing by cancer site: stomach
Abstract
Gastric cancer is a global public health concern, ranking as the fourth leading cause of cancer mortality, with a 5-year survival of only 20%. Approximately 10% of gastric cancers appear to have a familial predisposition, and about half of these can be attributed to hereditary germline mutations. We review the genetic syndromes and current standards for genetic counseling, testing, and medical management for screening and treatment of gastric cancer. Recently, germline mutations in the E-cadherin/CDH1 gene have been identified in families with an autosomal dominant inherited predisposition to gastric cancer of the diffuse type. The cumulative lifetime risk of developing gastric cancer in CDH1 mutation carriers is up to 80%, and women from these families also have an increased risk for developing lobular breast cancer. Prophylactic gastrectomies are recommended in unaffected CDH1 mutation carriers, because screening endoscopic examinations and blind biopsies have proven inadequate for surveillance. In addition to this syndrome, gastric cancer risk is elevated in Lynch syndrome associated with germline mutations in DNA mismatch repair genes and microsatellite instability, in hereditary breast and ovarian cancer syndrome due to germline BRCA1 and BRCA2 mutations, in familial adenomatous polyposis caused by germline APC mutations, in Li-Fraumeni syndrome due to germline p53 mutations, in Peutz-Jeghers syndrome associated with germline STK11 mutations, and in juvenile polyposis syndrome associated with germline mutations in the SMAD4 and BMPR1A genes. Guidelines for genetic testing, counseling, and management of individuals with hereditary diffuse gastric cancer are suggested. A raised awareness among the physician and genetic counseling communities regarding these syndromes may allow for increased detection and prevention of gastric cancers in these high-risk individuals.
Similar articles
-
[Hereditary gastric cancer. Genetics and clinical management].Rev Gastroenterol Mex. 2003 Jan-Mar;68(1):51-4. Rev Gastroenterol Mex. 2003. PMID: 12940100 Review. Spanish.
-
Hereditary gastric cancer.Best Pract Res Clin Gastroenterol. 2009;23(2):147-57. doi: 10.1016/j.bpg.2009.02.003. Best Pract Res Clin Gastroenterol. 2009. PMID: 19414142 Review.
-
Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1.Gastroenterology. 2015 Oct;149(4):897-906.e19. doi: 10.1053/j.gastro.2015.06.003. Epub 2015 Jun 11. Gastroenterology. 2015. PMID: 26072394
-
CDH1 associated gastric cancer: a report of a family and review of the literature.Eur J Surg Oncol. 2005 Apr;31(3):259-64. doi: 10.1016/j.ejso.2004.12.010. Eur J Surg Oncol. 2005. PMID: 15780560 Review.
-
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.Oncologist. 1996;1(5):326-330. Oncologist. 1996. PMID: 10388011
Cited by
-
Abnormal amphiregulin expression correlates with gastric cancer prognosis.Oncotarget. 2016 Nov 22;7(47):76684-76692. doi: 10.18632/oncotarget.12436. Oncotarget. 2016. PMID: 27713123 Free PMC article.
-
Hereditary gastric cancer: Three rules to reduce missed diagnoses.World J Gastroenterol. 2020 Apr 7;26(13):1382-1393. doi: 10.3748/wjg.v26.i13.1382. World J Gastroenterol. 2020. PMID: 32308342 Free PMC article. Review.
-
The Microbiome and Cancer: Is the 'Oncobiome' Mirage Real?Trends Cancer. 2015 Sep 1;1(1):24-35. doi: 10.1016/j.trecan.2015.07.005. Trends Cancer. 2015. PMID: 26568984 Free PMC article.
-
Improving the overall diagnostic rate of early gastric cancer by managing family members with hereditary cancer syndromes.Oncol Lett. 2020 Dec;20(6):295. doi: 10.3892/ol.2020.12158. Epub 2020 Sep 25. Oncol Lett. 2020. PMID: 33101489 Free PMC article. Review.
-
The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.BMC Cancer. 2021 Jan 5;21(1):20. doi: 10.1186/s12885-020-07764-7. BMC Cancer. 2021. PMID: 33402102 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous